Immunodermatology News

Providers should avoid monotherapy when treating hidradenitis suppurativa, and instead use a “layered and rotated” approach that also addresses the isolating psychosocial aspects of the disease, noted a speaker here.

Dermatologists should be prepared to discuss COVID-19 vaccines with their patients who have immune-mediated inflammatory diseases and how biologic treatments may be affected, according to a review.

Among patients with lupus erythematosus panniculitis resulting from cutaneous lupus erythematosus, male sex and discoid lupus erythematosus were risk factors for systemic lupus erythematosus development, according to a study.

Juvenile dermatomyositis challenges rheumatologists to accurately assess not only the skin but also pulmonary and cardiac function in making a diagnosis, according to a speaker at the 2021 Rheumatology Nurses Society annual conference.

Readmission rate for those with hidradenitis suppurativa may be comparable to the rate for those with heart failure at 180 days, according to a short communication analysis published in the Journal of the American Academy of Dermatology.

The FDA has approved intravenous immunoglobulin Octagam 10% for the treatment of adult dermatomyositis, Octapharma USA announced in a press release.

The COVID-19 pandemic has affected every portion of life for the past year and a half. In the dermatology world, it has had an impact on how specialists see their patients, as well as what they are treating.

The overall rate of hidradenitis suppurativa may be less than 0.5% of the general population, according to a meta-analysis.

Direct immunofluorescence microscopy bested serologic analysis as a diagnostic method for mucous membrane pemphigoid, according to a study.

Tofacitinib treatment in patients with sarcoidosis with cutaneous involvement delivered significant improvements, according to a study presented at AAD VMX 2021.